They've all reported solid fourth-quarter numbers in recent days.
Here's what traders should do now.
An analyst has reduced the rating on the healthcare stock to neutral, and its charts tend to support that decision.
Although pharmaceutical companies as a group are keeping pace with the broader market, there is considerable divergence in individual names.
Here's what I think we'll see up ahead.
Buyers of RAIN are still more aggressive than sellers.
These names are displaying both quantitative and technical deterioration.
The stock has been in a weak trend for more than a year.
Let's review the charts and indicators.
I was trying really hard to like CVS today, but I do not love this balance sheet.